Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price

Biosimilars Market 2022 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases), And By Region, Opportunities And Strategies – Global Forecast To 2031

Biosimilars Global Market Opportunities And Strategies To 2031

Starting Price : $5000.00 $3500.00 | Pages : 287 | Published : July 2022 | | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Biosimilars Market Definition

The biosimilars market consists of sales of biosimilars and related services that are used to treat chronic diseases such as diabetes, arthritis, and cancer. Biosimilars are pharmaceutical medicines that are manufactured using cell lines and which have been shown not to have any clinically meaningful differences from the originator or reference medicine in terms of quality, safety and efficacy.  Biosimilars can only be authorized once the period of data exclusivity on the reference biological medicine has expired.

Book your 30 minutes free consultation with our research experts

Contact Us

Biosimilars Market Size

The global biosimilars market size reached a value of nearly $11,418.9 million in 2021, having grown at a compound annual growth rate (CAGR) of 34.8% since 2016. The market is expected to grow from $11,418.9 million in 2021 to $25,985.2 million in 2026 at a rate of 17.3%. The market is then expected to grow at a CAGR of 18.0% from 2026 and reach $59,555.8 million in 2031.    

Growth in the historic period resulted from an increase in cancer prevalence, strong economic growth in emerging markets, an increase in pharmaceutical R&D expenditure, increased healthcare expenditure, growing government initiatives, strong pipeline of drugs, low cost of biosimilars and an increase in patent expiration. Factors that negatively affected growth in the historic period were regulatory changes, low healthcare access, lack of awareness on biosimilars among primary care physicians and specialists, reimbursement challenges, the coronavirus pandemic and low healthcare reimbursements.

Going forward, increasing prevalence of cancer, increasing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), a rise in healthcare expenditure, high potential of emerging economies, technology advances, high penetration of biological drugs, aging population and an increase in healthcare access will drive the growth. Factors that could hinder the growth of the biosimilars market in the future include high costs of drugs, high cost of drug development with threat of failure, pricing pressures from regulators and insufficient and outdated health system.

Biosimilars Market Drivers

The key drivers of the biosimilars market include:

High Penetration Of Biological Drugs

High penetration of the biologics is expected to be a driver of market growth during this period. Pharmaceutical companies are shifting towards originator biologics and competitive biosimilar drug development.  

Pharma companies had focused on small molecules for decades, but the rate of innovation in that field has slowed dramatically, leading to the shift towards biologics. These research and development (R&D) activities have led to increasing success rates in clinical trials. R&D is being carried out by market leaders  as they continuously strive to make breakthroughs in the form of new and effective biologics. This flow of originator biologics will provide the future substrate for biosimilar market growth

For instance, Amgen and Kirin Holdings Company are developing a filgrastim biosimilar which stimulates the growth of white blood cells to treat neutropenia, a common adverse event in patients receiving chemotherapy for breast cancer. Currently, the drug is in Phase I/II clinical study for breast cancer patients.  

In April 2022, the US Food and Drug Administration (FDA) approve the Biologics License Application (BLA) from Amneal Pharmaceuticals Inc for bevacizumab-maly, a biosimilar referencing Avastin, the Roche/Genentech product.  Therefore, high penetration of the biosimilar drugs is expected to drive the growth of the biosimilars market. Furthermore, the future growth of biosimilars will be on the back of new originator molecules or biologics.

Biosimilars Market Restraints

The key restraints on the biosimilars market include:

Insufficient And Outdated Health System

Insufficient and outdated health system infrastructure (facilities, technology, clinicians) remains, for many, a major hurdle to achieving health equity.

Fewer than 50% of Africans have access to modern health facilities. Further, around 61% of births were attended by skilled health staff in 2018, far fewer than the 80% global average. And although more people in India’s smaller towns and rural areas now have money for health care through the new PMSBY insurance scheme, they have limited options to use it because clinician and product supply is limited, and government health facilities are few and far between.

As of 2019, 9.6% of the 24,855 primary health centers (PHCs) in India had no doctor, 38.4% had no laboratory technician, and 23.9% had no pharmacist. There are also severe gaps in skilled professionals: For rural community health centers in 2019, only 15% of the surgical posts, 13% of the physician posts, 25% of the obstetrics and gynecology posts, and 20% of the pediatrician posts were filled.

Biosimilars Market Trends

Major trends shaping the biosimilars market include:

Robust Research & Development

The biosimilars market is witnessing robust research and development activities. These research and development activities have led to increasing success rates in clinical trials. Research and development is being carried out by market leaders in the biosimilars market as they continuously strive to make breakthroughs in the form of new and effective drugs.

In June 2020, Pfizer, an American multinational pharmaceutical company, received approval from the US Food and Drug Administration to introduce its biosimilar pegfilgrastim medicine Nyvepria for lowering the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs.

In May 2021, Zydus Cadila, launched the world’s first biosimilar antibody-drug conjugate of trastuzumab emtansine. The biosimilar, which uses Genentech/Roche’s trastuzumab emtansine (Kadcyla®) as the reference product, will be marketed under the name Ujvira®.  

In March 2020, AzarGen Biotechnologies (Pty) Ltd., a South Africa-based biotechnology company, in collaboration with iBio, Inc., a USA-based biotechnology company initiated its development activities of rituximab biosimilar.  AzarGen Biotechnologies is expected to utilize FastPharming System developed by iBio, Inc. to produce rituximab in plants.

Use of Robots and AI

The increasing adoption and use of robotics and artificial intelligence (AI) are key trends gaining popularity in the biosimilars market. Artificial intelligence is intelligence demonstrated by machines and is highly versatile.

Biomanufacturing and the designs of bioprocess facilities as well as associated manufacturing require excessive amounts of manual labor and manual interventions that lead to high labor costs and, consequently, the total cost to supply.

Targeted applications of mobile robots are expected to help decrease the dependency on manual labor and associated costs of biomanufacturing. Robots help execute various routine operations such as material handling, waste handling, material transport, hazardous operations, autonomous operations, and challenging tasks such as precision machining. Furthermore, robots are being developed to be smarter less expensive, and more versatile.

Opportunities And Recommendations In The Biosimilars Market

Opportunities –The top opportunities in the biosimilars market segmented by type will arise in the monoclonal antibodies segment, which will gain $8,508.0 million of global annual sales by 2026. The top opportunities in the biosimilars market segmented by application will arise in the oncology segment, which will gain $6,889.0 million of global annual sales by 2026. The biosimilars market size will gain the most in USA at $6,677.4 million.

Recommendations-To take advantage of the opportunities, The Business Research Company recommends the biosimilars companies to launch new products, invest in robotics and artificial intelligence (AI), expand in emerging markets, scale up through merger and acquisition activity, provide competitively priced offerings, continue to participate in events and conferences, take initiatives to educate consumers, target high-growth application areas and increase strategic partnerships.

Biosimilars Market Segmentation

The biosimilars market is segmented by type and by application.
By Type -
The biosimilars market is segmented by type into
    • a) Monoclonal Antibodies
    • b) Insulin
    • c) Erythropoietin
    • d) Granulocyte-Colony Stimulating Factor
    • e) Other Hormones
    • f) Others
The monoclonal antibodies market was the largest segment of the biosimilars market segmented by type, accounting for 39.6% of the total in 2021. Going forward, the erythropoietin segment is expected to be the fastest growing segment in the biosimilars market segmented by type, at a CAGR of 28.2% during 2021-2026.
By Application –
The biosimilars market is segmented by application into
    • a) Oncology
    • b) Chronic And Autoimmune Diseases
    • c) Growth Hormone Deficiency
    • d) Infectious Diseases
    • e) Other Applications
The biosimilars market is segment by geography into
By Geography - The biosimilars market is segment by geography into
      o Asia Pacific
      • • China
      • • India
      • • Japan
      • • Australia
      • • Indonesia
      • • South Korea
      o North America
      • • USA
      o South America
      • • Brazil
      o Western Europe
      • • France
      • • Germany
      • • UK
      o Eastern Europe
      • • Russia
      o Middle East
      o Africa
Western Europe was the largest region in the global biosimilars market, accounting for 66.0% of the total in 2021. It was followed by North America, and then the other regions. Going forward, the fastest-growing regions in the global biosimilars market will be Africa and Eastern Europe where growth will be at CAGRs of 117.0% and 60.1% respectively. These will be followed by South America and Middle East where the markets are expected to grow at CAGRs of 53.854% and 53.851% respectively.

Biosimilars Market Competitive Landscape

Major Competitors are:

  • Amgen
  • Pfizer
  • Novartis AG
  • Samsung Bioepis Co., Ltd.
  • Viatris

    • Other Competitors Include:

  • Biocon
  • Celltrion, Inc.
  • Coherus Biosciences
  • Elli Lilly and Company
  • Dr. Reddy's Laboratories
  • Roche India Pvt Ltd
  • Abbott India Limited
  • bioMérieux India
  • Becton Dickinson Private Limited
  • Danaher Corporation
  • Wuxi biologics
  • shanghai Henlius biotech
  • Innovent Biologics
  • Hisun Pharma
  • 3SBio
  • Beijing ShuangLu Pharmaceuticals
  • Qilu Pharmaceutical
  • Shanghai Fosun Pharmaceuticals
  • Mylan
  • Kyowa Hakko Kirin
  • Takeda
  • Mitsubishi Tanabe
  • AGC Biologics
  • Bio-Thera
  • Sandoz Pty Ltd
  • Apotex Pty Ltd
  • Cadila Pharmaceuticals
  • BiosanaPharma
  • GlaxoSmithKline
  • AstraZeneca
  • Bayer
  • Merck
  • Boehringer Ingelheim
  • Sanofi
  • Fresenius Kabi
  • Napp Pharmaceuticals
  • Mundipharma Deutschland GmbH & Co. KG
  • HARMONIE MEDICAL SERVICE Saint-Benoît
  • INSULET FRANCE SAS Paris
  • Microgen
  • Geropharm
  • Valenta
  • NovaMedica
  • SynBio
  • Rani Therapeutics
  • Emisphere Technologies, Inc.
  • Enteris BioPharma
  • Allena Pharmaceuticals
  • Abbvie
  • Johnson & Johnson
  • Biogen Inc.
  • Aché
  • Eurofarma
  • Teva Pharmaceuticals
  • Oramed Pharmaceuticals
  • Entera Bio
  • Julphar
  • Hikma Pharmaceuticals
  • BIOPHARMA-MEA
  • NeoTX
  • AID Genomics Limited
  • Altis Biologics
  • Cipla Medpro South Africa
  • Next Biosciences
  • Viome
  • Inqaba Biotechnical Industries (Pty)

      • Table Of Contents

      1. Biosimilars Market Executive Summary

      2. Table of Contents

      3. List of Figures

      4. List of Tables

      5. Report Structure

      6. Introduction and Market Characteristics

      6.1. General Market Definition

      6.2. Summary

      6.3. Market Segmentation By Type

      6.3.1. Monoclonal Antibodies

      6.3.2. Insulin

      6.3.3. Erythropoietin

      6.3.4. Granulocyte-Colony Stimulating Factor

      6.3.5. Other Hormones

      6.3.6. Other Types

      6.4. Market Segmentation By Application

      6.4.1. Oncology

      6.4.2. Chronic and Autoimmune Diseases

      6.4.3. Growth Hormone Deficiency

      6.4.4. Infectious Diseases

      6.4.5. Other Applications

      7. Major Market Trends

      7.1. Robust Research & Development

      7.2. Demand For Biosimilars In The Treatment Of Neutropenia

      7.3. Growing Mergers And Acquisitions

      7.4. Revised FDA Regulations To Facilitate Biosimilar Drug Development

      7.5. Large Number Of Strategic Partnerships

      7.6. Increasing Investments In Biosimilars Market

      7.7. Use of Robots and AI

      8. Global Market Size And Growth

      8.1. Market Size

      8.2. Historic Market Growth, 2016 – 2021, Value ($ Million)

      8.2.1. Market Drivers 2016 – 2021

      8.2.2. Market Restraints 2016 – 2021

      8.3. Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      8.3.1. Market Drivers 2021 – 2026

      8.3.2. Market Restraints 2021 – 2026

      9. Global Biosimilars Market Segmentation

      9.1. Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      9.2. Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      10. Biosimilars Market, Regional And Country Analysis

      10.1. Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      10.2. Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11. Asia-Pacific Market

      11.1.1. Summary

      11.2. Market Overview

      11.2.1. Region Information

      11.2.2. Market Information

      11.2.3. Background Information

      11.2.4. Government Initiatives

      11.2.5. Regulations

      11.2.6. Regulatory Bodies

      11.2.7. Major Associations

      11.2.8. Taxes Levied

      11.2.9. Corporate Tax Structure

      11.2.10. Investments

      11.2.11. Major Companies

      11.3. Asia-Pacific Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.4. Asia-Pacific Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.5. Asia-Pacific Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.6. Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.7. Asia-Pacific Biosimilars Market: Country Analysis

      11.8. China Market

      11.8.1. Summary

      11.9. Market Overview

      11.9.1. Country Information

      11.9.2. Market Information

      11.9.3. Background Information

      11.9.4. Government Initiatives

      11.9.5. Regulations

      11.9.6. Regulatory Bodies

      11.9.7. Major Associations

      11.9.8. Taxes Levied

      11.9.9. Corporate Tax Structure

      11.9.10. Investments

      11.9.11. Major Companies

      11.10. China Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.11. China Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.12. China Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.13. China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.14. India Biosimilars Market

      11.15. India Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.16. India Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.17. India Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.18. India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.19. Japan Biosimilars Market

      11.20. Japan Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.21. Japan Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.22. Japan Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.23. Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.24. Australia Biosimilars Market

      11.25. Australia Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.26. Australia Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.27. Australia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.28. Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.29. Indonesia Biosimilars Market

      11.30. Indonesia Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.31. Indonesia Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.32. Indonesia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.33. Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.34. South Korea Biosimilars Market

      11.35. South Korea Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      11.36. South Korea Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      11.37. South Korea Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      11.38. South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12. Western Europe Market

      12.1.1. Summary

      12.2. Market Overview

      12.2.1. Region Information

      12.2.2. Market Information

      12.2.3. Background Information

      12.2.4. Government Initiatives

      12.2.5. Regulations

      12.2.6. Regulatory bodies

      12.2.7. Major Associations

      12.2.8. Taxes Levied

      12.2.9. Corporate Tax Structure

      12.2.10. Investments

      12.2.11. Major Companies

      12.3. Western Europe Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      12.4. Western Europe Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      12.5. Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12.6. Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12.7. Western Europe Biosimilars Market: Country Analysis

      12.8. UK Biosimilars Market

      12.9. UK Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      12.10. UK Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      12.11. UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12.12. UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12.13. Germany Biosimilars Market

      12.14. Germany Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      12.15. Germany Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      12.16. Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12.17. Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12.18. France Biosimilars Market

      12.19. France Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      12.20. France Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      12.21. France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      12.22. France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13. Eastern Europe Market

      13.1.1. Summary

      13.2. Market Overview

      13.2.1. Region Information

      13.2.2. Market Information

      13.2.3. Background Information

      13.2.4. Government Initiatives

      13.2.5. Regulations

      13.2.6. Regulatory Bodies

      13.2.7. Major Associations

      13.2.8. Taxes Levied

      13.2.9. Corporate Tax Structure

      13.2.10. Investments

      13.2.11. Major Companies

      13.3. Eastern Europe Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      13.4. Eastern Europe Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      13.5. Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.6. Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.7. Eastern Europe Biosimilars Market: Country Analysis

      13.8. Russia Biosimilars Market

      13.9. Russia Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      13.10. Russia Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      13.11. Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      13.12. Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14. North America Market

      14.1.1. Summary

      14.2. Market Overview

      14.2.1. Region Information

      14.2.2. Market Information

      14.2.3. Background Information

      14.2.4. Government Initiatives

      14.2.5. Regulations

      14.2.6. Regulatory Bodies

      14.2.7. Major Associations

      14.2.8. Taxes Levied

      14.2.9. Corporate tax structure

      14.2.10. Investments

      14.2.11. Major Companies

      14.3. North America Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      14.4. North America Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      14.5. North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14.6. North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14.7. North America Biosimilars Market: Country Analysis

      14.8. USA Market

      14.8.1. Summary

      14.9. Market Overview

      14.9.1. Country Information

      14.9.2. Market Information

      14.9.3. Background Information

      14.9.4. Government Initiatives

      14.9.5. Regulations

      14.9.6. Regulatory Bodies

      14.9.7. Major Associations

      14.9.8. Taxes Levied

      14.9.9. Corporate Tax Structure

      14.9.10. Investments

      14.9.11. Major Companies

      14.10. USA Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      14.11. USA Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      14.12. USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      14.13. USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      15. South America Market

      15.1.1. Summary

      15.2. Market Overview

      15.2.1. Region Information

      15.2.2. Market Information

      15.2.3. Background Information

      15.2.4. Government Initiatives

      15.2.5. Regulatory Bodies

      15.2.6. Regulations

      15.2.7. Major Associations

      15.2.8. Taxes Levied

      15.2.9. Corporate Tax Structure

      15.2.10. Investments

      15.2.11. Major Companies

      15.3. South America Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      15.4. South America Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      15.5. South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      15.6. South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      15.7. South America Biosimilars Market: Country Analysis

      15.8. Brazil Biosimilars Market

      15.9. Brazil Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      15.10. Brazil Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      15.11. Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      15.12. Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      16. Middle East Market

      16.1.1. Summary

      16.2. Market Overview

      16.2.1. Region Information

      16.2.2. Market Information

      16.2.3. Background information

      16.2.4. Government Initiatives

      16.2.5. Regulatory Bodies

      16.2.6. Regulations

      16.2.7. Major Associations

      16.2.8. Taxes Levied

      16.2.9. Corporate Tax Structure

      16.2.10. Investments

      16.2.11. Major Companies

      16.3. Middle East Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      16.4. Middle East Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      16.5. Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      16.6. Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      17. Africa Market

      17.1.1. Summary

      17.2. Market Overview

      17.2.1. Region Information

      17.2.2. Market Information

      17.2.3. Background Information

      17.2.4. Government Initiatives

      17.2.5. Regulations

      17.2.6. Regulatory Bodies

      17.2.7. Major Associations

      17.2.8. Taxes Levied

      17.2.9. Corporate Tax Structure

      17.2.10. Investments

      17.2.11. Major Companies

      17.3. Africa Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

      17.4. Africa Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

      17.5. Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      17.6. Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

      18. Competitive Landscape And Company Profiles

      18.1. Company Profiles

      18.2. Amgen Inc.

      18.2.1. Company Overview

      18.2.2. Products And Services

      18.2.3. Business Strategy

      18.2.4. Financial Overview

      18.3. Pfizer Inc.

      18.3.1. Company Overview

      18.3.2. Products And Services

      18.3.3. Business Strategy

      18.3.4. Financial Overview

      18.4. Novartis AG

      18.4.1. Company Overview

      18.4.2. Products And Services

      18.4.3. Business Strategy

      18.4.4. Financial Overview

      18.5. Samsung Bioepis Co., Ltd.

      18.5.1. Company Overview

      18.5.2. Products And Services

      18.5.3. Business Strategy

      18.5.4. Financial Overview

      18.6. Viatris Inc.

      18.6.1. Company Overview

      18.6.2. Products And Services

      18.6.3. Business Strategy

      18.6.4. Financial Overview

      19. Pipeline Analysis

      20. Key Mergers And Acquisitions In The Biosimilars Market

      20.1. Fresenius Kabi Acquired mAbxience

      20.2. Biocon Biologics to Acquire Viatris Biosimilars Business

      20.3. AbCellera Acquired TetraGenetics

      20.4. Celltrion Acquired Assets Of Takeda Pharmaceuticals

      20.5. Ligand Pharmaceuticals Acquired Pfenex

      20.6. ChrysCapital Acquired Stakes In Intas Pharmaceuticals

      20.7. Amgen Acquired Japanese JV with Astellas

      20.8. True North Acquired Stake In Biocon Biologics Ltd.

      20.9. Biocon Acquired Research and Development (R&D) Facility from Pfizer Healthcare India

      20.10. PAG Acquired Hisun BioRay Bio-pharmaceutical Co., Ltd.

      20.11. Pfizer Inc. Acquired Array BioPharma Inc.

      20.12. Samsung Bioepis Enters Into An Agreement With C-Bridge Capital

      20.13. Fuji Pharma Co., Ltd. Acquired Stake In Alvotech

      20.14. Kashiv Pharma Acquired Adello Biologics

      20.15. Bristol-Myers Squibb Acquired Celgene Corporation

      20.16. Takeda Pharmaceutical Company Limited Acquired Shire Plc

      20.17. Amneal Pharmaceuticals Merge With Impax Laboratories

      20.18. Biocon Merged With Sandoz

      21. Global Biosimilars Market Opportunities And Strategies

      21.1. Global Biosimilars Market In 2026 – Countries Offering Most New Opportunities

      21.2. Global Biosimilars Market In 2026 – Segments Offering Most New Opportunities

      21.3. Global Biosimilars Market In 2026 – Growth Strategies

      21.3.1. Market Trend Based Strategies

      21.3.2. Competitor Strategies

      22. Biosimilars Market, Conclusions And Recommendations

      22.1. Conclusions

      22.2. Recommendations

      22.2.1. Product

      22.2.2. Place

      22.2.3. Price

      22.2.4. Promotion

      22.2.5. People

      23. Appendix

      23.1. Market Data Sources

      23.2. Research Methodology

      23.3. Currencies

      23.4. The Business Research Company

      24. Copyright and Disclaimer

    List Of Tables

      Table 1: Global Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 2: Global Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 3: Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 4: Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 5: Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 6: Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 7: Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 8: Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 9: Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 10: Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 11: Asia-Pacific Population By Age Group, By Country, 2016-2026, Thousands
    • Table 12: Asia-Pacific GDP Per Capita, By Country, 2016-2021, $
    • Table 13: Asia-Pacific Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 14:  Asia-Pacific Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 15: Asia-Pacific, Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 16: Asia-Pacific Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 17: Asia-Pacific Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 18: Asia-Pacific Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 19: Asia-Pacific Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 20: Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 21: Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 22: China Population By Age Group, 2016-2026, Thousands
    • Table 23: China GDP Per Capita, 2016-2021, $
    • Table 24:  China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 25: China Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 26: China Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 27: China Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 28: China Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 29: China Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 30: China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 31: China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 32: India Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 33: India Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 34: India Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 35: India Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 36: India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 37: India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 38: Japan Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 39: Japan Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 40: Japan Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 41: Japan Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 42: Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 43: Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 44: Australia Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 45: Australia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 46: Australia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 47: Australia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 48: Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 49: Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 50: Indonesia Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 51: Indonesia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 52: Indonesia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 53: Indonesia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 54: Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 55: Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 56: South Korea Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 57: South Korea Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 58: South Korea Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 59: South Korea Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 60: South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 61: South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 62: Western Europe Population By Age Group, By Country, 2016-2026, Thousands
    • Table 63: Western Europe GDP Per Capita, By Country, 2016-2021, $
    • Table 64:  Western Europe Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 65:  Western Europe Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 66: Western Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 67: Western Europe Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 68: Western Europe Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 69: Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 70: Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 71: Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 72: Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 73: UK Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 74: UK Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 75: UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 76: UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 77: UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 78: UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 79: Germany Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 80: Germany Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 81: Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 82: Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 83: Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 84: Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 85: France Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 86: France Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 87: France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 88: France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 89: France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 90: France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 91: Eastern Europe Population By Age Group, By Country, 2016-2026, Thousands
    • Table 92: Eastern Europe GDP Per Capita, By Country, 2016-2021, $
    • Table 93:  Eastern Europe Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 94:  Eastern Europe Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 95: Eastern Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 96: Eastern Europe Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 97: Eastern Europe Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 98: Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 99: Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 100: Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 101: Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 102: Russia Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 103: Russia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 104: Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 105: Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 106: Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 107: Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 108: North America Population By Age Group, By Country, 2016-2026, Thousands
    • Table 109: North America GDP Per Capita, By Country, 2016-2021, $
    • Table 110:  North America Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 111:  North America Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 112: North America Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 113: North America Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 114: North America Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 115: North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 116: North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 117: North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 118: North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 119: USA Population By Age Group, 2016-2026, Thousands
    • Table 120: USA GDP Per Capita, 2016-2021, $
    • Table 121:  USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 122: USA Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 123: USA Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 124: USA Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 125: USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 126: USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 127: USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 128: USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 129: South America Population By Age Group, By Country, 2016-2026, Thousands
    • Table 130: South America GDP Per Capita, By Country, 2016-2021, $
    • Table 131:  South America Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 132:  South America Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 133: South America Healthcare Services Market Size, By Country, 2016-2026, $ Billion
    • Table 134: South America Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 135: South America Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 136: South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 137: South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 138: South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 139: South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 140: Brazil Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 141: Brazil Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 142: Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 143: Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 144: Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 145: Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 146: Middle East Population By Age Group, By Country, 2016-2026, Thousands
    • Table 147: Middle East GDP Per Capita, By Country, 2016-2021, $
    • Table 148:  Middle East Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 149:  Middle East Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 150: Middle East Healthcare Services Market Size, 2016-2021, $ Billion
    • Table 151: Middle East Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 152: Middle East Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 153: Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 154: Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 155: Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 156: Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 157: Africa Population By Age Group, By Country, 2016-2026, Thousands
    • Table 158: Africa GDP Per Capita, By Country, 2016-2021, $
    • Table 159:  Africa Public Healthcare Expenditure, 2015-2020, $ Billion
    • Table 160:  Africa Private Healthcare Expenditure, 2015-2020, $ Billion
    • Table 161: Africa Healthcare Services Market Size, 2016-2021, $ Billion
    • Table 162: Africa Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Table 163: Africa Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Table 164: Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 165: Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 166: Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Table 167: Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
    • Table 168: Global Smart Wearables Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)
    • Table 169: Amgen Inc. – Financial Overview, 2017 - 2021, $ Billion
    • Table 170: Pfizer Inc. – Financial Overview, 2017 - 2021, $ Billion
    • Table 171: Novartis AG – Financial Overview, 2017 - 2021, $ Billion
    • Table 172: Viatris Inc. – Financial Overview, 2017 - 2021, $ Billion
    • Table 173: Global Biosimilars Market, Pipeline Analysis
    • Table 174: Global Biosimilars Market Size Gain ($ Million), 2021 – 2026, By Country
    • Table 175: Global Biosimilars Market Size Gain ($ Million), Segmentation By Type, 2021 – 2026
    • Table 176: Global Biosimilars Market Size Gain ($ Million), Segmentation By Application, 2021 – 2026
    • Table 177: Biosimilars Market Data Sources

    List Of Figures

      Figure 1: Geographic Regions Covered
    • Figure 2: Global Biosimilars Market Segmentation By Type
    • Figure 3: Global Biosimilars Market Segmentation By Application
    • Figure 4: Global Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 5: Global Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 6: Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 7: Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 8: Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 9: Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 10: Asia-Pacific Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 11: Asia-Pacific Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 12: Asia-Pacific Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 13: Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 14: China Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 15: China Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 16: China Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 17: China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 18: India Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 19: India Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 20: India Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 21: India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 22: Japan Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 23: Japan Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 24: Japan Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 25: Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 26: Australia Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 27: Australia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 28: Australia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 29: Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 30: Indonesia Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 31: Indonesia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 32: Indonesia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 33: Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 34: South Korea Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 35: South Korea Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 36: South Korea Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 37: South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 38: Western Europe Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 39: Western Europe Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 40: Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 41: Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 42: UK Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 43: UK Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 44: UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 45: UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 46: Germany Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 47: Germany Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 48: Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 49: Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 50: France Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 51: France Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 52: France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 53: France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 54: Eastern Europe Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 55: Eastern Europe Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 56: Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 57: Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 58: Russia Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 59: Russia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 60: Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 61: Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 62: North America Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 63: North America Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 64: North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 65: North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 66: USA Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 67: USA Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 68: USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 69: USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 70: South America Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 71: South America Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 72: South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 73: South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 74: Brazil Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 75: Brazil Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 76: Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 77: Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 78: Middle East Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 79: Middle East Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 80: Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 81: Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 82: Africa Biosimilars Market, Historic, 2016 – 2021, $ Million
    • Figure 83: Africa Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
    • Figure 84: Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 85: Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
    • Figure 86: Global biosimilars Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)
    • Figure 87: Amgen Inc. – Financial Overview, 2017 – 2021, $ Billion
    • Figure 88: Pfizer Inc. – Financial Overview, 2017 – 2021, $ Billion
    • Figure 89: Novartis AG – Financial Overview, 2017 – 2021, $ Billion
    • Figure 90: Viatris Inc. – Financial Overview, 2017 – 2021, $ Billion

    The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

    Read More

    The Biosimilar Therapeutic Peptides Market Share, Market Size, And Growth Rate 2022

    Read More

    Global Anticoagulants Market 2022 – Market Opportunities And Strategies

    Read More

    What Is The Compression Therapy Market Overview In 2022?

    Read More

    The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

    Read More

    The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

    Read More

    The Business Research Company offers the stem cell therapy market research report 2022 with industry size, share, segments and market growth

    Read More

    The Business Research Company offers the regenerative medicine for cartilage market research report 2022 with industry size, share, segments and market growth

    Read More

    CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

    View Report

    Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030

    View Report

    Cellular Immunotherapy Global Market Report 2024 – By Therapy (Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy), By Primary Indication (B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications), By Application (Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications ) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Oral Biologics & Biosimilar Drugs Global Market Report 2024 – By Therapy (Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors), By Disease (Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Digestive Enzymes Global Market Report 2024 – By Enzyme Type (Carbohydrates, Protease, Lipase, Other Enzyme Types), By Origin (Animal, Fungi, Microbial, Plant), By Application (Indigestion, Chronic Pancreatitis, Irritable Bowel Syndrome, Other Applications), By Distribution Channel (Retail Stores, Online Stores) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Oncology Biosimilars Global Market Report 2024 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Corticosteroids Global Market Report 2024 – By Product (Glucocorticoids, Mineralocorticoids), By Application (Skin Allergies, Rheumatology Indications, Endocrinology, Acute Respiratory Diseases, Other Applications), By End User (Hospitals, Clinics, Research Institutes, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Interferons Global Market Report 2024 – By Type (Interferon Alpha, Interferon Beta, Interferon Gamma), By Application (Hepatitis B, Hepatitis C, Melanoma, Leukemia, Multiple Sclerosis, Renal Cell Carcinoma), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2024-2033

    View Report